Pakistan continues to be dealing with a polio outbreak as four fresh cases have emerged, pushing the national tally to 37 this year, according to health officials on October 19, 2024. Health officials said that the regional reference laboratory for polio eradication at the National Institute of Health in Islamabad confirmed wild poliovirus type-1 (WPV1) in two children-one from each Balochistan and Khyber-Pakhtunkhwa.

In recent cases, a girl has been affected from Pishin, and two boys from Chaman and Noshki of Balochistan, and a girl from Lakki Marwat in KP. These are the first detections of the virus within Noshki and Lakki Marwat this year; isolated cases of poliovirus were previously reported within Chaman and Pishin. The province of Balochistan was the worst hit with 20 cases, Sindh had 10, Khyber Pakhtunkhwa had five, and Punjab and Islamabad had one case each.

A gigantic fight against polio has been on going in Pakistan- especially in Balochistan and southern KP-over the last two years. Immunisation campaigns have often been suspended or delayed because of local protests, insecurity, and community boycotts. Consequently, quite a number of children did not get the necessary vaccinations, making existing patches of vulnerability for the virus to flow within those pockets.

Noshki, located near Afghanistan's border, and Lakki Marwat have also recently reported some positive environmental samples that confirm the virus is present here, said a local reference laboratory official. Samples of latest cases are currently under genetic sequencing for checking spread of virus and origin.

As the threat of polio continues to grow, Pakistan has vowed to mount a nationwide campaign against it beginning from October 28. With the zeal to tackle the menace in the most effective manner, over 45 million children under the age of five will be vaccinated across the country.

Today, Afghanistan and Pakistan remain one of the few countries where polio has not yet been eradicated. The WHO said the virus remains a potential serious public health threat in areas with low vaccination coverage and weak surveillance.

India On Alert Against Polio

The country declared itself polio-free since 2014 and has kept the disease on bay almost a decade with very robust vaccination programs; however, two cases of vaccine-derived poliovirus cases reported in recent days from Meghalaya create some amount of doubts over a possible resurgence. Experts observe that in India, despite these detections taking place, strong coverage of vaccination at 90-95% and mandatory surveillance measures keep the risk of this widespread outbreak at bay.

The experts point out, however, that such stable situation in India requires continued surveillance. "Countries like Pakistan and parts of Africa remain at a high risk because vaccination rates in those areas are much lower," Dr. Siddharth, public health expert, said. Vaccination is an indispensable act in order to avoid the spread of this incapacitating disease that manifests most importantly as a nervous system affliction leading to the paralysis of a long period.

With concerted efforts from health authorities, there is hope someday that the scourge of polio will be completely eradicated from the face of the earth and future generations will never suffer from its effects.

One of the most common viruses in the world could be behind lupus, an autoimmune condition with a wide range of symptoms, according to a study released Wednesday. Lupus has long puzzled doctors: No single cause has been identified, and there is no standard treatment.

However, new research, published in Science Translational Medicine, suggests that Epstein-Barr virus, which infects 95% of people at some point in their lives, may trigger lupus by prompting the body to attack its own healthy cells.

Also Read: New Malaria Drug 2025: GanLum Outperforms Standard Treatment, Could Save Millions

Epstein-Barr Virus: What Is It?

Epstein-Barr virus (EBV) is a widespread herpesvirus that infects most people globally and is the main cause of infectious mononucleosis, also called mono. It spreads primarily through saliva, meaning kissing, sharing drinks, or close personal contact can pass the virus.

For most, EBV causes a short-lived illness with symptoms such as fatigue, fever, and sore throat. Once infected, the virus stays in the body for life, often without causing further problems, though it has been linked to certain cancers and autoimmune diseases, especially in people with weaker immune systems, according to the Centers for Disease Control and Prevention.

This adds to growing evidence connecting EBV to long-term health issues, including autoimmune conditions. Researchers say the findings strengthen the case for developing a vaccine targeting the virus.

In people with lupus, the immune system attacks the body, causing extreme fatigue, joint pain, and skin rashes. In rare cases, the disease can lead to serious complications like kidney damage or make the body less able to fight infections.

Also Read: Botulism Infant Formula Recall 2025: ByHeart Expands Nationwide Recall After 15 Babies Hospitalized

Epstein-Barr Virus and the Lupus Link

Scientists have long suspected a connection between EBV and lupus, but the exact link remained unclear. Dr. William Robinson, co-author of the study and chief of immunology and rheumatology at Stanford University, said the new findings solve a key piece of the puzzle.

“From our perspective, it’s the missing mechanistic link,” Robinson said. “We believe it could apply to all lupus cases,” he added. Hundreds of thousands in the U.S. live with the disease.

However, Hoang Nguyen, assistant vice president of research at the Lupus Research Alliance, cautioned that it’s too early to say whether this mechanism explains every case, as per NBC News.

“While the evidence is promising, more research is needed to confirm if EBV is the trigger for all lupus,” Nguyen said. The alliance, a private funder of lupus research, provided grant support for the study.

Epstein-Barr Virus Transmission

Not everyone infected with EBV shows symptoms, especially children, although the virus is the most common cause of mononucleosis. It spreads mainly through saliva, by kissing or sharing drinks, food, utensils, or toothbrushes. Once in the body, EBV usually stays dormant, though sometimes it reactivates.

This isn’t the first time EBV has been tied to autoimmune disorders. Earlier research has linked it to multiple sclerosis, though it is likely one factor among many in the disease’s development.

Robinson noted that the pathway his team identified might also contribute to other autoimmune diseases, including rheumatoid arthritis and Crohn’s disease, though more work is needed to explore that.

Most people infected with EBV never develop lupus, MS, or other autoimmune conditions. Robinson said certain strains of EBV may be more likely to trigger autoimmune reactions.

Epstein-Barr Virus: What Diseases Are Associated With Epstein Barr Virus?

To explore the link with lupus, Robinson and colleagues focused on B cells, white blood cells that fight infections. Even in healthy people, EBV lies dormant in a small portion of B cells. But in lupus patients, these infected B cells are far more common — up to 25 times higher than in healthy individuals, according to the study.

The research also highlights antinuclear antibodies, proteins that attach to cell nuclei and are a hallmark of lupus. Epstein-Barr infects B cells and reprograms them to produce these antibodies, which then attack healthy tissue.

Robinson said the findings align with other theories of lupus, including genetic and hormonal factors that may make someone more vulnerable to the disease. A 2024 *Nature* study also found lupus patients have too many of a certain T cell type associated with cell damage, and too few T cells that aid repair. The pathway Robinson describes could trigger these immune responses.

Epstein-Barr Virus: Is Treatment Possible?

The study points to new possibilities for lupus therapy. Currently, treatments mainly reduce inflammation, such as corticosteroids. Robinson said future drugs could target B cells infected with EBV specifically.

Meanwhile, vaccines in clinical trials could prevent EBV infection entirely. “Vaccination to stop EBV infection would be the ultimate way to prevent these autoimmune diseases,” Robinson said, as per NBC News.

A new and potentially life-saving step in the fight against malaria has surfaced as Novartis announced a promising drug combination that could prove crucial in regions where existing treatments are becoming less effective. Malaria continues to claim nearly 600,000 lives every year, though that number was once around 2 million about 25 years ago. The rise in deaths has been linked to the parasite’s growing resistance to long-used drugs, said George Jagoe, Executive Vice President for Access and Product Management at Medicines for Malaria Venture (MMV). Thankfully, a new malaria medicine now shows real promise as an effective tool against resistant strains.

Also Read: Amid Delhi's Toxic Smog And Severe AQI, Authorities Implement GRAP-3 Measures; What Does It Mean For People?

New Malaria Treatments Show Promise As Drug Resistance Grows

On Wednesday, researchers revealed two new ways to fight the growing problem of malaria resistance, one of which involves a fresh class of drugs. Swiss pharmaceutical company Novartis shared results of what it called a next-generation therapy. The study, conducted in 12 African countries, showed that its experimental drug worked effectively against the malaria parasite and also appeared to prevent transmission.

What Is GanLum?

The new drug, known as ganaplacide/lumefantrine or GanLum, was jointly developed by Novartis and Medicines for Malaria Venture, a non-profit organisation. According to Reuters, it was more than 97% successful in treating malaria during a phase III trial involving 1,688 adults and children across 34 sites in 12 African countries, Novartis reported. Malaria still kills more than 600,000 people each year, most of them children under five in sub-Saharan Africa.

Also Read: Byheart Formula Recall Update: 2 More Infants Hospitalized, FDA Says

GanLum is given as a packet of fine powder once daily for three days. However, getting patients to complete multi-day treatment remains a challenge. Many people stop after the first or second dose, once they begin to feel better. Experts estimate that about one-third of malaria patients fail to finish the full course, which can increase drug resistance and worsen otherwise curable infections.

In a separate study, researchers testing a one-time treatment found that a single dose made up of four commonly available malaria medicines worked well in curing the infection. Both studies were presented on Wednesday at the American Society of Tropical Medicine and Hygiene conference in Toronto.

Parasite Has Repeatedly Developed Drug Resistance

Malaria is caused by a parasite transmitted through mosquito bites. Infected individuals experience fever, chills, and flu-like symptoms that, if untreated, can become severe and even fatal. The disease primarily affects tropical and subtropical regions, with the highest death toll seen among children in sub-Saharan Africa.

The medical community’s fight against malaria has seen highs and lows as new treatments appear, only for the parasite to eventually develop resistance.

At the turn of this century, resistance to the once-effective chloroquine became widespread, and malaria deaths climbed to over 1.8 million annually. The introduction of a new group of drugs known as artemisinins helped reduce global malaria deaths dramatically.

As per NHS, today, artemisinin-based therapies remain the standard treatment. Yet, early signs of partial resistance have begun to appear, and due to several factors, global malaria death rates have either stagnated or started to rise in certain regions.

Experimental Treatment Shows Promise

GanLum, developed by Novartis, combines a new compound, ganaplacide, with an existing long-acting medication, lumefantrine. In a trial involving around 1,700 adults and children across 12 African nations, GanLum achieved a cure rate exceeding 97%, slightly higher than that of standard artemisinin-based therapies. It also proved highly effective against mutated malaria parasites that show partial resistance, according to Novartis officials.

Reported side effects included fever and anemia, similar to those seen with other antimalarial drugs. There was also a higher rate of vomiting immediately after administration, which experts suggest may be related to the drug’s taste. The company has said it is exploring ways to make it more palatable, such as by adding flavouring or sweeteners, Reuters reported.

As Delhi's air quality continues to deteriorate, and reached emergency levels on Tuesday, as per the official data, it has been declared to be the worst in nearly 11 months. As a result, Graded Response Action Plan (GRAP) Stage-3 has been implemented in Delhi.

As of Tuesday, the city's average AQI as per the official data, stood at 428, this is worst since December 19 of last year, when the index read 451. This is a sharp rise from 362 AQI on Monday. Visibility too dropped to 600 metres at Safdarjung and 700 metres at Palam at 6.30am. The Central Pollution Control Board (CPCB) data continued to record 'severe' air quality levels across Delhi-NCR even on Wednesday morning.

You May Like To Read: Delhi Air Pollution: Think Pollution Only Hurts Your Lungs? Doctors Say It Can Cause Strokes Too

What Does GRAP 3 Mean For People?

GRAP is a 9-point action plan that is being implemented to bring down pollution. The restrictions are imposed in Delhi, and comprises a list of the type of vehicles, which are allowed in the national capital. This means, if you do not live in Delhi, and are travelling via Delhi, you will also have to comply with the rules. Failure to do so may invite penalty.

As per the Commission for Air Quality Management (CAQM)'s statement: "Considering the ongoing trend in air quality and to prevent further decline, the sub-committee has decided to implement all measures under Stage III of GRAP – ‘Severe’ air quality (Delhi AQI between 401 and 450) – with immediate effect across the NCR."

Read: Delhi Sees A 60% Surge In Patients With Eye Problems Due To Worsening Air Pollution, According To Doctor

Which Zones Are Affected?

The enforcement zones include Delhi and NCR too, including Gurugram, Faridabad, Ghaziabad, Gautam Buddha Nagar.

Are There Any Other Restrictions?

The restriction is not only on the vehicles, but also on dust-generating construction and demolition activities. The restrictions also include:

• Demolition Work
• Excavation or Earthwork, which includes laying sewer, water, drainage, or electrical lines
• Brick or masonry work
• Major welding and gas-cutting operations
• Painting, cementing, plastering, or coating work
• Tile cutting, grinding, and fixing
• Waterproofing and road repair or construction work
• Loading, unloading, or transfer of dust-generating materials
• Movement of vehicles carrying construction materials on unpaved roads
• Transportation of demolition waste

Read More: 1 in 7 Deaths In Delhi In 2023 Were Caused By Air Pollution, Revealed Study

The Delhi Government has also announced that schools up to Class V would be conducted in hybrid mode. Apart from this, all stone crushers and mining operations across NCR has been ordered to shut down.

What Are The GRAP Stages?

GRAP operates on a tiered system, with different stages corresponding to varying levels of AQI. The goal is to implement specific measures at each stage to curb pollution and reduce public health risks. The different stages of GRAP are:

• Stage I: It is triggered when the AQI falls in the range of 201-300, which indicates “poor” to “very poor” air quality.

• Stage II: This happens when the AQI reaches between 301 and 400, reflecting “very poor” to “severe” conditions.

• Stage III: This is implemented when the AQI exceeds 400, which is categorized as “severe” air quality. This stage triggers more stringent measures to reduce pollution levels, with a focus on restricting outdoor activities, vehicle use, and industrial operations.

How Does Pollution Impact One's Health?

Chronic pollution exposure aggravates oxidative stress and systemic inflammation. This means, with every breath you take, you inhale a toxic swamp.

As per Pusan National University, long term air pollution exposure actually triggers allergic immune responses in the lungs. Furthermore, a 2022 study published in the International Journal of Environmental Research and Public Health also shows the negative impact on immune system with alarming and harmful air quality.

As per another 2000 study, published by the British Society for Immunology, people living in areas with higher pollution levels show measurably different immune responses than those in cleaner environment.

Air pollution contains toxins like particulate matter, ozone, carbon monoxide, nitrogen dioxide, and sulfur dioxide. It also includes hazardous air pollutants (HAPs), such as lead, mercury, asbestos, benzene, and other volatile organic compounds. When one breathes this toxic and poisonous air the respiratory system bears the initial brunt of it. The pollutants then damage the delicate tissues lining your airways, and disrupts the barrier that normally prevents harmful substances from entering your body. When this first line of defense is compromised, pathogens find it easier to established infections.